FLGT Fulgent Genetics, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1674930 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.7%
TTM net income YoY-111.5%
TTM EPS YoY-135.1%
Revenue 3-yr CAGR4.9%
Net income 3-yr CAGR—
Margins
Gross margin33.8%
Operating margin-39.2%
Net margin-27.5%
FCF margin-0.4%
EBITDA margin-32.8%
Returns
ROE-8.6%
ROA-7.9%
ROIC (approx.)-10.7%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets8.7%
Debt / equity0.00x
Current ratio5.34x
Interest coverage-1,307.88x
Cash quality & payout
Operating cash flow / net income-0.16x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue4.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $322.67M | $283.47M |
| Cost of revenue | $191.80M | $176.25M |
| Gross profit | $130.88M | $107.22M |
| R&D expense | $53.91M | $48.82M |
| SG&A expense | $116.66M | $88.11M |
| Operating income | -$91.10M | -$73.92M |
| Interest expense | $75,000 | -$170,000 |
| Pretax income | -$70.03M | -$51.96M |
| Income tax | -$8.39M | -$8.14M |
| Net income | -$60.51M | -$42.71M |
| EBITDA | -$66.97M | -$48.99M |
| EPS (diluted) | — | — |
| Weighted avg. shares (diluted) | 30.78M | 30.23M |
| Balance sheet | ||
| Cash & equivalents | $50.19M | $55.28M |
| Short-term investments | $285.88M | $202.96M |
| Receivables | $84.76M | $69.02M |
| Current assets | $550.49M | $353.57M |
| PP&E, net | $112.55M | $105.55M |
| Goodwill | $25.08M | $22.05M |
| Intangibles | $133.28M | $134.98M |
| Total assets | $1.21B | $1.22B |
| Current liabilities | $84.97M | $72.90M |
| Total liabilities | $106.81M | $90.81M |
| Shareholders' equity | $1.11B | $1.13B |
| Shares outstanding | 31.08M | 30.84M |
| Cash flow statement | ||
| Operating cash flow | -$101.64M | $21.06M |
| Capital expenditure | $22.57M | $40.31M |
| Free cash flow | -$124.21M | -$19.25M |
| Investing cash flow | $111.37M | -$58.35M |
| Financing cash flow | -$14.79M | -$4.85M |
| Depreciation & amortization | $24.12M | $24.93M |
| Stock-based compensation | $39.58M | $44.48M |
| Share buybacks | $10.88M | $225,000 |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.